in search of biomarker of response to IL-2 that can be validated in subsequent studies. Table 1 Response by Baseline Characteristics The therapeutic armamentarium for metastatic RCC considerably expanded in the past several years with
Search Results
Saby George, Roberto Pili, Michael A. Carducci, and Jenny J. Kim
Christopher P. Chung, Carolyn Behrendt, Louise Wong, Sarah Flores, and Joanne E. Mortimer
classified according to the IIQ-7 score as major (33–99), moderate (5–29), or no impact (0). Statistical Analyses For this exploratory study, statistical significance ( P <.05) was unadjusted for multiple hypothesis testing. Demographic characteristics (age
Melissa S.Y. Thong, Daniel Boakye, Lina Jansen, Uwe M. Martens, Jenny Chang-Claude, Michael Hoffmeister, Hermann Brenner, and Volker Arndt
of demographic and clinical characteristics by CCIS were tested for statistical significance using either an analysis of variance for continuous variables or a chi-square test for categorical variables. We used multivariable linear regression to
Kathryn P. Lowry, Katherine A. Callaway, Janie M. Lee, Fang Zhang, Dennis Ross-Degnan, J. Frank Wharam, Karla Kerlikowske, Karen J. Wernli, Allison W. Kurian, Louise M. Henderson, and Natasha K. Stout
enrollment. Results Cohort Selection and Characteristics Of 27,456,015 women enrolled from 2004 to 2016, we identified 141,672 aged 40 to 64 years with evidence of a personal breast cancer history meeting our inclusion/exclusion criteria
Matthew P. Banegas, Donna R. Rivera, Maureen C. O’Keeffe-Rosetti, Nikki M. Carroll, Pamala A. Pawloski, David C. Tabano, Mara M. Epstein, Kai Yeung, Mark C. Hornbrook, Christine Lu, and Debra P. Ritzwoller
standards. 22 VTR data were obtained via chart review by trained abstractors and included data associated with health service use and clinical, treatment, and tumor characteristics. The VDW pharmacy files provided data on national drug code
Samuel Martel, Matteo Lambertini, Dominique Agbor-Tarh, Noam F. Ponde, Andrea Gombos, Vicki Paterson, Florentine Hilbers, Larissa Korde, Anna Manukyants, Amylou Dueck, Christian Maurer, Martine Piccart, Alvaro Moreno-Aspitia, Christine Desmedt, Serena Di Cosimo, and Evandro de Azambuja
original ALTTO trial. 10 Statistical Considerations Patient baseline characteristics were compared with respect to BMI category (underweight, normal weight, overweight, obese) using the chi-square test. Weight change was calculated as a percentage (by
Heidi Ko, Yaser Baghdadi, Charito Love, and Joseph A. Sparano
for categorical variables. Association Between Clinical Characteristics and Upstaging Frequencies Associations between clinical characteristics and upstaging frequencies were assessed using the Fisher exact test for categorical variables and the
Randy C. Miles, Christoph I. Lee, Qin Sun, Aasthaa Bansal, Gary H. Lyman, Jennifer M. Specht, Catherine R. Fedorenko, Mikael Anne Greenwood-Hickman, Scott D. Ramsey, and Janie M. Lee
. Clinical data included age at diagnosis, race, diagnosis year, family history of breast cancer, and breast cancer–specific genetic mutation status. Tumor characteristic data included AJCC stage, grade, size, and estrogen receptor (ER), progesterone receptor
Abi Vijenthira, Lee Mozessohn, Chenthila Nagamuthu, Ning Liu, Danielle Blunt, Shabbir Alibhai, Anca Prica, and Matthew C. Cheung
frequency and percentages where appropriate. The Student t test was used to compare baseline characteristics, frailty scores, and chemoimmunotherapy cycles received between frail and nonfrail patients. The chi-square test was used to compare categorical
Benjamin M. Parsons, Dipesh Uprety, Angela L. Smith, Andrew J. Borgert, and Leah L. Dietrich
potential associations between sociodemographic, stage, estrogen receptor (ER)/progesterone receptor (PR) status, and tumor and treatment characteristics using Pearson chi-square or Fisher exact tests. Survival analysis using Kaplan-Meier curves Figure 1
